Filing Details
- Accession Number:
- 0000950170-24-032406
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2024-03-15 19:14:06
- Reporting Period:
- 2024-01-09
- Accepted Time:
- 2024-03-15 19:14:06
- Original Submission Date:
- 2024-01-11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1400973 | F John Crowley | 47 Hulfish Street Princeton NJ 08542 | Executive Chairman | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-09 | 57,620 | $0.00 | 995,492 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-01-09 | 36,865 | $13.65 | 958,627 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2024-01-10 | 31,614 | $13.65 | 927,013 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Footnotes
- Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
- On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
